



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:
Marina Konopleva *et al.*

Serial No.: 09/998,009

Filed: November 28, 2001


For: CDDO-COMPOUNDS AND
COMBINATION THERAPIES THEREOF

Group Art Unit: 1635

Examiner: Unknown

Atty. Dkt. No.: UTSC:652US

#12
RECEIVED
APR 30 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
April 21, 2003	
Date	
Priya D. Subramony	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX DD

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

25281071.1

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:652US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 21, 2003

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:652USSerial No.
09/998,009

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant
Marina Konopleva *et al.*Filing Date:
November 28, 2001Group:
1635U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents							
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 99/65478	12/23/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Ito <i>et al.</i> , "The novel triterpenoid 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism," <i>Cell Growth & Differentiation</i> , 11(5):261-267, 2000.
	C29	Konopleva <i>et al.</i> , "Novel synthetic triterpenoid CDDO-Me: potent antiproliferative, proapoptotic and differentiating agent in AML," <i>Blood</i> , 96(11), Part 1: 121A, abstract # 522, 2000.
	C30	Ruvolo <i>et al.</i> , "The novel triterpenoid methyl-CDDO inhibits Bc12 phosphorylation and potently kills U937 cells," <i>Blood</i> , 94(10), Suppl. 1, Part 1: 280A, abstract #1251, 1999.
	C31	Suh <i>et al.</i> , "A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), induces cell differentiation in human myeloid leukemias," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 40:300, abstract # 1988, 1999.
	C32	Wang <i>et al.</i> , "A novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) induces adipocyte differentiation in 3T3-L1 cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 40:300, abstract # 1989, 1999.

25280096.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
TECH CENTER 1600/2000
APR 3 0 2003



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

PSUBRAMONY@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3067

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 21, 2003

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: BOX DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
April 21, 2003	Date
Priya D. Subramony	

BOX DD

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 09/998,009 entitled "CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF" – Marina Konopleva et al.*
Our reference: UTSC:652US
Client reference: MDA00-010

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references B1, C28-C32.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:652US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Priya D. Subramony
Patent Agent
Reg. No. 50,939

PDS/cmb
Encl.: as noted
25281079.1

GPH/1633

RECEIVED
TECH CENTER 1600/2000
APR 30 2003